exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089312 RNA Name: hsa-miR-7-5p RNA Type: miRNA Chromosome: chr19 Starnd: + Coordinate: Start Site(bp): 4770700 End Site(bp): 4770723 External Links: hsa-miR-7-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand RCC2 chr1 17406760 17439677 - GNA12 chr7 2728105 2844308 - RAB29 chr1 205767986 205775482 - TSPAN14 chr10 80454166 80533124 + INTS2 chr17 61865367 61928016 - ACVR1B chr12 51951699 51997078 + RPS6KB1 chr17 59893046 59950574 + SCD chr10 100347233 100364826 + INSR chr19 7112255 7294414 - SLC25A44 chr1 156193932 156212796 + KMT2D chr12 49018975 49059774 - ORAI1 chr12 121626550 121642677 + ATXN1 chr6 16299112 16761491 - NAPA chr19 47487637 47515091 - HP1BP3 chr1 20740266 20787323 - SETD7 chr4 139495941 139606699 - PLXNA1 chr3 126988594 127037392 + KLHL18 chr3 47282917 47346816 + IRS2 chr13 109752695 109786583 - CBL chr11 119206298 119313926 + VPS4A chr16 69311350 69326939 + DNAJC9 chr10 73183362 73247255 - PATL1 chr11 59636716 59669037 - MEPCE chr7 100428790 100434118 + FYCO1 chr3 45917899 45995824 - JAM3 chr11 134069071 134152001 + HMGA2 chr12 65824131 65966295 + TM4SF1 chr3 149369022 149377692 - DHCR24 chr1 54849627 54887195 - RUSC1 chr1 155320894 155331114 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000712 chr16 68208276 68225678 + hsa_circ_0001168 chr20 47691321 47707559 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC016876.2 chr17 7581964 7584086 - AC105339.2 chr15 82752884 82757208 + AL096870.2 chr14 24209646 24215987 - AL590617.2 chr6 138692548 138697288 + MIR497HG chr17 7015818 7019659 - OIP5-AS1 chr15 41283990 41309737 + SNHG1 chr11 62851984 62855953 - TBC1D3P1-DHX40P1 chr17 59962363 60018975 - U91328.1 chr6 25992641 26001775 + XIST chrX 73820649 73852723 - ZFAS1 chr20 49278178 49299600 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.